scholarly article | Q13442814 |
P356 | DOI | 10.1046/J.1365-2133.1999.02889.X |
P8608 | Fatcat ID | release_wgsyuusvxjh5ba4jvnmwlgsg3i |
P698 | PubMed publication ID | 10354086 |
P2093 | author name string | Burg G | |
Nestle FO | |||
Dummer R | |||
Kleinhans M | |||
Fritz TM | |||
P2860 | cites work | Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results | Q28300282 |
Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). | Q34333859 | ||
A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides | Q40768413 | ||
The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas | Q40809016 | ||
Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution | Q41262862 | ||
Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. | Q50868440 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | interferon alfa | Q6046441 |
P304 | page(s) | 1144-1147 | |
P577 | publication date | 1999-06-01 | |
P1433 | published in | British Journal of Dermatology | Q4970191 |
P1476 | title | Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome | |
P478 | volume | 140 |
Q37944565 | Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management |
Q27024076 | Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management |
Q36470196 | Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management |
Q48034709 | Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. |
Q35622833 | Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. |
Q38010239 | Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art. |
Q34560665 | Immunomodulators in the treatment of cutaneous lymphomas |
Q35612026 | Interferon in the treatment of cutaneous T-cell lymphoma |
Q35622819 | Selective immmunotherapy through extracorporeal photochemotherapy: yesterday, today, and tomorrow |
Q33625948 | The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society |
Q37954015 | The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas |
Q35612038 | The treatment of cutaneous T-cell lymphoma with photopheresis |
Q34547470 | Therapy for mycosis fungoides |
Q37074253 | U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease |
Q84471693 | [Extracorporeal photopheresis in dermatology] |